JP5269466B2 - 経口摂取用組成物 - Google Patents
経口摂取用組成物 Download PDFInfo
- Publication number
- JP5269466B2 JP5269466B2 JP2008105753A JP2008105753A JP5269466B2 JP 5269466 B2 JP5269466 B2 JP 5269466B2 JP 2008105753 A JP2008105753 A JP 2008105753A JP 2008105753 A JP2008105753 A JP 2008105753A JP 5269466 B2 JP5269466 B2 JP 5269466B2
- Authority
- JP
- Japan
- Prior art keywords
- spirulina
- composition
- nash
- esr
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 45
- 230000037406 food intake Effects 0.000 title claims description 11
- 240000002900 Arthrospira platensis Species 0.000 claims description 61
- 235000016425 Arthrospira platensis Nutrition 0.000 claims description 61
- 229940082787 spirulina Drugs 0.000 claims description 59
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 49
- 230000002292 Radical scavenging effect Effects 0.000 claims description 28
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 18
- 230000002265 prevention Effects 0.000 claims description 12
- 239000004480 active ingredient Substances 0.000 claims description 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 3
- 238000004435 EPR spectroscopy Methods 0.000 claims description 2
- 238000000804 electron spin resonance spectroscopy Methods 0.000 description 41
- 230000036542 oxidative stress Effects 0.000 description 31
- 239000000843 powder Substances 0.000 description 26
- 150000003254 radicals Chemical class 0.000 description 22
- 235000013305 food Nutrition 0.000 description 20
- 238000005259 measurement Methods 0.000 description 20
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 239000000047 product Substances 0.000 description 16
- VCUVETGKTILCLC-UHFFFAOYSA-N 5,5-dimethyl-1-pyrroline N-oxide Chemical compound CC1(C)CCC=[N+]1[O-] VCUVETGKTILCLC-UHFFFAOYSA-N 0.000 description 15
- 239000003642 reactive oxygen metabolite Substances 0.000 description 15
- 230000001575 pathological effect Effects 0.000 description 14
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 13
- 239000001301 oxygen Substances 0.000 description 13
- 229910052760 oxygen Inorganic materials 0.000 description 13
- 241000700159 Rattus Species 0.000 description 12
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 11
- 210000005228 liver tissue Anatomy 0.000 description 11
- 239000011572 manganese Substances 0.000 description 11
- OSKIWEPJAIOTFB-UHFFFAOYSA-N 5,5-dimethyl-2-(2-methyl-1-oxido-3,4-dihydropyrrol-1-ium-2-yl)-1,3,2$l^{5}-dioxaphosphinane 2-oxide Chemical compound O1CC(C)(C)COP1(=O)C1(C)CCC=[N+]1[O-] OSKIWEPJAIOTFB-UHFFFAOYSA-N 0.000 description 10
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 10
- 210000002311 liver mitochondria Anatomy 0.000 description 10
- 230000002438 mitochondrial effect Effects 0.000 description 9
- -1 oxygen radical Chemical class 0.000 description 9
- 239000001103 potassium chloride Substances 0.000 description 9
- 235000011164 potassium chloride Nutrition 0.000 description 9
- 238000010171 animal model Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000001362 electron spin resonance spectrum Methods 0.000 description 8
- 229930006000 Sucrose Natural products 0.000 description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 229910052742 iron Inorganic materials 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 239000012488 sample solution Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 239000005720 sucrose Substances 0.000 description 7
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 6
- 230000008021 deposition Effects 0.000 description 6
- 238000009795 derivation Methods 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 210000003462 vein Anatomy 0.000 description 6
- 208000004930 Fatty Liver Diseases 0.000 description 5
- 206010019708 Hepatic steatosis Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 208000010706 fatty liver disease Diseases 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 208000006454 hepatitis Diseases 0.000 description 5
- 231100000283 hepatitis Toxicity 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 210000003240 portal vein Anatomy 0.000 description 5
- 231100000240 steatosis hepatitis Toxicity 0.000 description 5
- 206010016654 Fibrosis Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000003494 hepatocyte Anatomy 0.000 description 4
- 230000002000 scavenging effect Effects 0.000 description 4
- 230000001953 sensory effect Effects 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000037149 energy metabolism Effects 0.000 description 3
- 230000004761 fibrosis Effects 0.000 description 3
- 231100001026 histopathological changes in livers Toxicity 0.000 description 3
- 210000003470 mitochondria Anatomy 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 3
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 3
- 235000012149 noodles Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 2
- 108010053210 Phycocyanin Proteins 0.000 description 2
- 241000405792 Spirulina major Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- NLEBIOOXCVAHBD-QKMCSOCLSA-N dodecyl beta-D-maltoside Chemical compound O[C@@H]1[C@@H](O)[C@H](OCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 NLEBIOOXCVAHBD-QKMCSOCLSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000001146 hypoxic effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 229960003330 pentetic acid Drugs 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 238000013319 spin trapping Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000001631 vena cava inferior Anatomy 0.000 description 2
- NFFCPZZYYGLLFL-UHFFFAOYSA-N 3-hydroxy-2,5,7,8-tetramethyl-3,4-dihydrochromene-2-carboxylic acid Chemical compound C1C(O)C(C)(C(O)=O)OC2=C(C)C(C)=CC(C)=C21 NFFCPZZYYGLLFL-UHFFFAOYSA-N 0.000 description 1
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 1
- 241000531072 Arthrospira fusiformis Species 0.000 description 1
- 241000620196 Arthrospira maxima Species 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 102000006404 Mitochondrial Proteins Human genes 0.000 description 1
- 108010058682 Mitochondrial Proteins Proteins 0.000 description 1
- 238000013231 NASH rodent model Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000549834 Spirulina laxissima Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 1
- 230000009285 allergic inflammation Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000011325 biochemical measurement Methods 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- WDRWZVWLVBXVOI-QTNFYWBSSA-L dipotassium;(2s)-2-aminopentanedioate Chemical compound [K+].[K+].[O-]C(=O)[C@@H](N)CCC([O-])=O WDRWZVWLVBXVOI-QTNFYWBSSA-L 0.000 description 1
- WPUMTJGUQUYPIV-JIZZDEOASA-L disodium (S)-malate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](O)CC([O-])=O WPUMTJGUQUYPIV-JIZZDEOASA-L 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000002864 food coloring agent Nutrition 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- DCYOBGZUOMKFPA-UHFFFAOYSA-N iron(2+);iron(3+);octadecacyanide Chemical compound [Fe+2].[Fe+2].[Fe+2].[Fe+3].[Fe+3].[Fe+3].[Fe+3].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] DCYOBGZUOMKFPA-UHFFFAOYSA-N 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000008204 material by function Substances 0.000 description 1
- WVJKHCGMRZGIJH-UHFFFAOYSA-N methanetriamine Chemical compound NC(N)N WVJKHCGMRZGIJH-UHFFFAOYSA-N 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- CMFNMSMUKZHDEY-UHFFFAOYSA-N peroxynitrous acid Chemical compound OON=O CMFNMSMUKZHDEY-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010408 sweeping Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/748—Cyanobacteria, i.e. blue-green bacteria or blue-green algae, e.g. spirulina
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Mycology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
Description
H」と呼称する)等の肝炎の予防又は治療の少なくとも一方に用いる経口摂取用組成物に
関するものである。
本発明に係る経口摂取用組成物として実施例1を製造した。この実施例1の経口摂取用組成物はスピルリナ100%の粉末を使用した。
乾燥スピルリナ粉末を分離型ドレッシングに配合することにより、実施例2の経口摂取用組成物とした。乾燥スピルリナ粉末は株式会社スピルリナ研究所製造のスピルリナパウダーであり、分離型ドレッシングはキューピー株式会社の市販品を使用した。乾燥スピルリナ粉末は分離型ドレッシングの全量に対して、0.01重量%、0.1重量%、1.0重量%、5.0重量%の各割合で添加したものを製造した。
実験的に調整された脂肪肝担持ラットに対し、酸化ストレス(OS)を負荷し、生体内低酸素状態を形成させることによりNASHの生化学的・病理組織学的特徴を有する病態モデルラットを作出し、このものに対し、本発明の経口摂取用組成物を投与し、該ラットの血液の生化学的特徴変化、肝臓ミトコンドリアからのROS派生の変化、肝臓組織の病理組織学的変化を観察することにより、NASHに対する本発明の経口摂取用組成物の有効性評価を行った。
<本発明の経口摂取用組成物による肝臓ミトコンドリアからのフリーラジカル産生抑制効果>
本発明の経口摂取用組成物によるNASH病態モデル動物の肝臓ミトコンドリアのエネルギー代謝からの活性酸素・フリーラジカルの派生増大に対する是正効果をみるため、下記試験を実施した。
Claims (3)
- 非アルコール性脂肪性肝炎の予防又は治療に用いる経口摂取用組成物であって、スピルリナを有効成分として含有して成ることを特徴とする経口摂取用組成物。
- 乾燥状態のスピルリナを少なくとも0.1重量%含有して成ることを特徴とする請求項1に記載の経口摂取用組成物。
- 電子スピン共鳴分光−スピントラップ法で測定した時のヒドロキシルラジカル消去能がIC50値として3000乃至100μg/mlであることを特徴とする請求項1又は2に記載の経口摂取用組成物。
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008105753A JP5269466B2 (ja) | 2008-04-15 | 2008-04-15 | 経口摂取用組成物 |
PCT/JP2009/050034 WO2009128279A1 (ja) | 2008-04-15 | 2009-01-06 | 経口摂取用組成物 |
US12/937,725 US20110091424A1 (en) | 2008-04-15 | 2009-01-06 | Oral dosage composition |
SG2013025515A SG189752A1 (en) | 2008-04-15 | 2009-01-06 | Oral dosage composition |
CN200980113164.2A CN102006877B (zh) | 2008-04-15 | 2009-01-06 | 口服组合物 |
MYPI2010004829A MY155299A (en) | 2008-04-15 | 2009-01-06 | Oral dosage composition |
TW98100872A TW200944220A (en) | 2008-04-15 | 2009-01-10 | Composition for oral ingestion |
HK11108566.4A HK1154484A1 (en) | 2008-04-15 | 2011-08-16 | Oral dosage composition |
US13/846,768 US9132157B2 (en) | 2008-04-15 | 2013-03-18 | Oral dosage composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008105753A JP5269466B2 (ja) | 2008-04-15 | 2008-04-15 | 経口摂取用組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009256230A JP2009256230A (ja) | 2009-11-05 |
JP5269466B2 true JP5269466B2 (ja) | 2013-08-21 |
Family
ID=41198980
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008105753A Active JP5269466B2 (ja) | 2008-04-15 | 2008-04-15 | 経口摂取用組成物 |
Country Status (8)
Country | Link |
---|---|
US (2) | US20110091424A1 (ja) |
JP (1) | JP5269466B2 (ja) |
CN (1) | CN102006877B (ja) |
HK (1) | HK1154484A1 (ja) |
MY (1) | MY155299A (ja) |
SG (1) | SG189752A1 (ja) |
TW (1) | TW200944220A (ja) |
WO (1) | WO2009128279A1 (ja) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2708577A1 (de) | 2012-09-13 | 2014-03-19 | Basf Se | Polyurethane enthaltend halogenverbindungen |
EP2799459A1 (de) | 2013-05-03 | 2014-11-05 | Basf Se | Polyurethane enthaltend Halogenverbindungen |
ES2704427T3 (es) | 2012-09-13 | 2019-03-18 | Basf Se | Poliuretanos que contienen compuestos de halógenos |
KR102298332B1 (ko) | 2013-12-02 | 2021-09-07 | 바스프 에스이 | 감소된 알데히드 방출을 갖는 폴리우레탄 |
JP6698526B2 (ja) | 2013-12-02 | 2020-05-27 | ビーエーエスエフ ソシエタス・ヨーロピアBasf Se | 低減されたアルデヒドの排出を有するポリウレタン |
EP3155030B1 (de) | 2014-06-13 | 2018-03-28 | Basf Se | Polyurethane mit reduzierter aldehydemission |
DK3186293T3 (en) | 2014-08-28 | 2019-01-21 | Basf Se | AGE-RESISTANT POLYURETIC SEAL |
US20180086872A1 (en) | 2015-04-17 | 2018-03-29 | Basf Se | Polyurethanes with reduced aldehyde emission |
KR20180014001A (ko) | 2015-05-28 | 2018-02-07 | 바스프 에스이 | 알데히드 방출이 감소된 폴리우레탄 |
KR102394670B1 (ko) | 2016-05-12 | 2022-05-09 | 바스프 에스이 | 고 밀도를 갖는 점탄성 폼 |
CN109196011A (zh) | 2016-06-03 | 2019-01-11 | 巴斯夫欧洲公司 | 具有减少的醛释放的聚氨酯 |
WO2017217340A1 (ja) * | 2016-06-13 | 2017-12-21 | 国立大学法人九州大学 | フリーラジカル消費速度情報の取得方法およびnashの判定方法 |
US10604257B2 (en) * | 2016-06-28 | 2020-03-31 | International Business Machines Corporation | Unmanned aerial vehicle for air sampling |
US11814469B2 (en) | 2018-02-02 | 2023-11-14 | Basf Se | Polyurethanes having low emissions of organic compounds |
WO2020020709A1 (de) | 2018-07-25 | 2020-01-30 | Basf Se | Silikonfreie schaumstabilisatoren für die herstellung von polyurethanschaumstoffen |
KR20230111230A (ko) | 2020-11-25 | 2023-07-25 | 바스프 에스이 | 알데히드 방출이 감소된 폴리우레탄 |
KR20240021891A (ko) | 2021-06-14 | 2024-02-19 | 바스프 에스이 | 알데히드 스캐빈저로서의 폴리아민 |
WO2024052451A1 (en) | 2022-09-09 | 2024-03-14 | Basf Se | Battery potting material with improved adhesion to metal |
WO2024104923A1 (en) | 2022-11-16 | 2024-05-23 | Basf Se | Manganese- and iron-containing catalysts comprising an imine ligand for the synthesis of polyurethanes |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07289201A (ja) | 1994-04-20 | 1995-11-07 | Supirurina Kenkyusho:Kk | スピルリナ食品の製造方法 |
JP2001190244A (ja) | 2000-01-11 | 2001-07-17 | Tokai Sangyo Kk | スピルリナからの青色色素の製造方法 |
JP2004238519A (ja) | 2003-02-06 | 2004-08-26 | Microalgae Corporation | 抗酸化作用と紫外線吸収作用を有する抽出物、皮膚外用剤及び食品 |
JP2004256478A (ja) | 2003-02-27 | 2004-09-16 | Dainippon Ink & Chem Inc | 免疫グロブリンa抗体産生促進剤 |
JP4677250B2 (ja) | 2005-02-24 | 2011-04-27 | Dicライフテック株式会社 | 藍藻類からのフィコシアニンの抽出方法 |
US7326558B2 (en) * | 2005-03-16 | 2008-02-05 | Dainippon Ink And Chemicals, Inc. | Process for treating spirulina |
CN1833661A (zh) | 2006-01-12 | 2006-09-20 | 石圣洪 | 螺旋藻咀嚼片及其制备方法 |
JP2007215507A (ja) * | 2006-02-17 | 2007-08-30 | Kobayashi Pharmaceut Co Ltd | スピルリナおよびクロレラ含有食品組成物 |
-
2008
- 2008-04-15 JP JP2008105753A patent/JP5269466B2/ja active Active
-
2009
- 2009-01-06 SG SG2013025515A patent/SG189752A1/en unknown
- 2009-01-06 CN CN200980113164.2A patent/CN102006877B/zh active Active
- 2009-01-06 MY MYPI2010004829A patent/MY155299A/en unknown
- 2009-01-06 US US12/937,725 patent/US20110091424A1/en not_active Abandoned
- 2009-01-06 WO PCT/JP2009/050034 patent/WO2009128279A1/ja active Application Filing
- 2009-01-10 TW TW98100872A patent/TW200944220A/zh unknown
-
2011
- 2011-08-16 HK HK11108566.4A patent/HK1154484A1/xx unknown
-
2013
- 2013-03-18 US US13/846,768 patent/US9132157B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2009256230A (ja) | 2009-11-05 |
MY155299A (en) | 2015-09-30 |
US20130236421A1 (en) | 2013-09-12 |
US9132157B2 (en) | 2015-09-15 |
HK1154484A1 (en) | 2012-04-27 |
CN102006877A (zh) | 2011-04-06 |
CN102006877B (zh) | 2014-05-07 |
SG189752A1 (en) | 2013-05-31 |
TW200944220A (en) | 2009-11-01 |
US20110091424A1 (en) | 2011-04-21 |
WO2009128279A1 (ja) | 2009-10-22 |
TWI376228B (ja) | 2012-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5269466B2 (ja) | 経口摂取用組成物 | |
Wang et al. | Purification and characterisation of a novel antioxidant peptide derived from blue mussel (Mytilus edulis) protein hydrolysate | |
Komarnytsky et al. | Potato protease inhibitors inhibit food intake and increase circulating cholecystokinin levels by a trypsin-dependent mechanism | |
Wang et al. | Free radical scavenging and immunomodulatory activities of Ganoderma lucidum polysaccharides derivatives | |
Prahalathan et al. | Morin attenuates blood pressure and oxidative stress in deoxycorticosterone acetate-salt hypertensive rats: a biochemical and histopathological evaluation | |
US9687438B2 (en) | Method for enhancing collagen secretion and preventing cutaneous aging using chenopodium formosanum extract | |
Zhao et al. | Concomitant ingestion of lactic acid bacteria and black tea synergistically enhances flavonoid bioavailability and attenuates D-galactose-induced oxidative stress in mice via modulating glutathione antioxidant system | |
Chen et al. | Djulis (Chenopodium formosanum) and its bioactive compounds affect vasodilation, angiotensin converting enzyme activity, and hypertension | |
Zhou et al. | Nicotinamide mononucleotide combined with lactobacillus fermentum TKSN041 reduces the photoaging damage in murine skin by activating AMPK signaling pathway | |
Sirin et al. | Protective effect of exopolysaccharides from lactic acid bacteria against amyloid beta1-42induced oxidative stress in SH-SY5Y cells: Involvement of the AKT, MAPK, and NF-κB signaling pathway | |
Garzarella et al. | Evaluating the effects of a standardized polyphenol mixture extracted from poplar-type propolis on healthy and diseased human gut microbiota | |
Nepal et al. | Abresham ameliorates dyslipidemia, hepatic steatosis and hypertension in high-fat diet fed rats by repressing oxidative stress, TNF-α and normalizing NO production | |
Seyydi et al. | Exercise and Urtica Dioica extract ameliorate mitochondrial function and the expression of cardiac muscle Nuclear Respiratory Factor 2 and Peroxisome proliferator-activated receptor Gamma Coactivator 1-alpha in STZ-induced diabetic rats | |
Xia et al. | Lactobacillus plantarum AR113 attenuates liver injury in D-galactose-induced aging mice via the inhibition of oxidative stress and endoplasmic reticulum stress | |
Ololade Zacchaeus et al. | Black velvet tamarind: phytochemical analysis, antiradical and antimicrobial properties of the seed extract for human therapeutic and health benefits | |
Shen et al. | Protective activity of Malus doumeri leaf extract on H2O2-induced oxidative injury in H9C2 rat cardiomyocytes | |
JP2009102247A (ja) | 非アルコール性脂肪性肝炎に有効な経口摂取用組成物 | |
WO2022234511A2 (en) | Compositions based on bacterial strains for the treatment of alterations in carbohydrate metabolism | |
KR20150076999A (ko) | 항산화 및 미백 활성이 증진된 굴 추출물의 제조방법 | |
JP5761695B2 (ja) | 非アルコール性脂肪性肝炎に有効な経口摂取用組成物 | |
Imai et al. | Effect of propolis supplementation on the redox state of human serum albumin during high-intensity kendo training | |
Aizman et al. | The mechanisms of Curcuma longa rhizome action on glucose metabolism in alloxan–induced diabetic rats | |
Li et al. | Andrias davidianus bone peptides alleviates hyperuricemia-induced kidney damage in vitro and in vivo | |
Abdel-Atty et al. | Biological and Biochemical Effect of Green Peas and Lentils Sprouts on Rats with Fatty Liver | |
KR20140000767A (ko) | 치커리 추출물의 근육 손상 예방, 치료 또는 개선을 위한 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110214 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130122 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130325 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130409 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130508 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5269466 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |